357
Beirut, Lebanon – 2019: The National Social Security Fund (NSSF) has recently announced the reimbursement of new Multiple Sclerosis medication by 95%. The new product will further help control this challenging disease. MS is an autoimmune disease that affects the central nervous system when immune cells in the body begin to attack parts of the brain and the system itself, damaging the myelin sheaths that cover the neurons in the brain and spinal cord.
The new product is characterized for its short treatment period and long term benefit, helping patients overcome the burden of the disease.